The findings emerged as scientists search for an inexpensive antiviral drug that can treat patients with severe COVID-19 infection.
The Spanish study published in ScienceDirect was conducted on 50-76 patients hospitalized with COVID-19. These patients were treated with calcifediol and only one of these patients required admission to the ICU. The rest of the patients were discharged without complications.
People who did not receive the drug, some of them were admitted to intensive care and two died. “Our pilot study showed that administration of a high dose of calcifediol or 25-hydroxyvitamin D, the major metabolite of the endocrine system of vitamin D, significantly reduced the need for ICU treatment for patients requiring hospitalization. because of the proven Covid-1
Calcifediol has been shown to be able to reduce the risk of severe COVID infection, although more large group studies are needed to establish a definitive response.